Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00505661 · OUTCOME

Objective Response Rate Following Treatment With Letrozole

Letrozole in Patients With Ovarian Tumors · Source last updated 2012-04-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
2 month intervals for first 2 years

What was measured

Using RECIST criteria, Objective Response evaluated every 2 months.

Analysis population: Analysis was per protocol, only 9 of 12 eligible patients were evaluable for response.

Groups in this outcome

Letrozole

2.5 mg by mouth (PO) daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Letrozole9

Reported measurements

Complete Response
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Letrozole0Not reportedNot reportedNot reportedNot reported
Partial Response
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Letrozole0Not reportedNot reportedNot reportedNot reported
Stable Disease
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Letrozole3Not reportedNot reportedNot reportedNot reported
Progressive Disease
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Letrozole6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Complete Response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Partial Response
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Stable Disease
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Progressive Disease
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    units
    Participants
description
Using RECIST criteria, Objective Response evaluated every 2 months.
groups
  1. description
    2.5 mg by mouth (PO) daily
    id
    OG000
    title
    Letrozole
param Type
NUMBER
population Description
Analysis was per protocol, only 9 of 12 eligible patients were evaluable for response.
reporting Status
POSTED
time Frame
2 month intervals for first 2 years
title
Objective Response Rate Following Treatment With Letrozole
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice